PRODUCTS

Reagents

PRODUCTS

Reagents

High quality reagents for use with our assays and controls.

ASRs

Invivoscribe offers Analyte Specific Reagents (ASRs) targeting FLT3 ITD, FLT3 TKD, B- and T-cell antigen receptor loci, as well as IGH-BCL2, BCR-ABL1, and PML-RARα chromosome translocations.

The analyte specific reagents offered by Invivoscribe are PCR master mixes containing all components necessary for PCR other than polymerase. Analyte specific reagents are available only in the US. Analytical and performance characteristics are not established.

VIEW AVAILABLE PRODUCTS ⟶

Enzymes

FalconTaq is the gold standard of hot start polymerases and has demonstrated robust performance in many Invivoscribe assays, including our Minimal Residual Disease (MRD) applications.

Research use only (RUO)

VIEW AVAILABLE PRODUCTS ⟶

Hi-Di Formamide

Highly deionized (Hi-Di) Formamide with ROX size standards for ABI ﬂuorescence detection with the ABI 310 or 3100 series.

Research use only (RUO)

VIEW AVAILABLE PRODUCTS ⟶

REAGENTS

Invivoscribe Launches LeukoStratKMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide

2026-02-05T14:09:13-08:00February 4th, 2026|2026 Press Releases, Press Releases|

Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia

2025-11-24T09:51:38-08:00November 24th, 2025|2025 Publications, Featured Publications, Publications|

QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3–Internal Tandem Duplications for Treatment With Quizartinib

2025-10-28T11:29:07-07:00September 3rd, 2025|2025 Publications, Featured Publications, Publications|

A Systematic, Evidence-Based Workflow for Classifying KMT2A Fusions in AML

2025-07-29T15:39:42-07:00July 29th, 2025|2025 Publications, Featured Publications, Publications|

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial

2026-03-09T18:04:28-07:00July 7th, 2025|2025 Press Releases, Press Releases|

ALL RELATED ARTICLES ⟶

REAGENTS

Invivoscribe Launches LeukoStratKMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide

2026-02-05T14:09:13-08:00February 4th, 2026|2026 Press Releases, Press Releases|

Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia

2025-11-24T09:51:38-08:00November 24th, 2025|2025 Publications, Featured Publications, Publications|

QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3–Internal Tandem Duplications for Treatment With Quizartinib

2025-10-28T11:29:07-07:00September 3rd, 2025|2025 Publications, Featured Publications, Publications|

A Systematic, Evidence-Based Workflow for Classifying KMT2A Fusions in AML

2025-07-29T15:39:42-07:00July 29th, 2025|2025 Publications, Featured Publications, Publications|

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial

2026-03-09T18:04:28-07:00July 7th, 2025|2025 Press Releases, Press Releases|

ALL RELATED ARTICLES ⟶

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

PRODUCTS

Reagents

PRODUCTS

Reagents

High quality reagents for use with our assays and controls.

High quality reagents for use with our assays and controls.

ASRs

Invivoscribe offers Analyte Specific Reagents (ASRs) targeting FLT3 ITD, FLT3 TKD, B- and T-cell antigen receptor loci, as well as IGH-BCL2, BCR-ABL1, and PML-RARα chromosome translocations.

The analyte specific reagents offered by Invivoscribe are PCR master mixes containing all components necessary for PCR other than polymerase. Analyte specific reagents are available only in the US. Analytical and performance characteristics are not established.

Enzymes

FalconTaq is the gold standard of hot start polymerases and has demonstrated robust performance in many Invivoscribe assays, including our Minimal Residual Disease (MRD) applications.

Research use only (RUO)

Hi-Di Formamide

Highly deionized (Hi-Di) Formamide with ROX size standards for ABI ﬂuorescence detection with the ABI 310 or 3100 series.

Research use only (RUO)

REAGENTS

Related Articles

REAGENTS

Related Articles

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.